WuXi PharmaTech Supplies Laboratory Testing Services to Lee's Pharm
PTSM: Pharmaceutical Technology Sourcing and Management
WuXi's Laboratory Testing Division will be the exclusive supplier of laboratory testing services for Hong Kong-based Lee's Pharm.
WuXi PharmaTech and Lee's Pharm, a research-based biopharmaceutical company headquartered in Hong Kong with operations in China, announced on Aug. 26, 2015 that the two companies have signed an agreement whereby WuXi's Laboratory Testing Division (LTD) will be the exclusive supplier of laboratory testing services for Lee's Pharm. These services will include LTD's entire portfolio of discovery and investigational new drug/new drug application package services, including chemistry analytical services, in-vitro and in-vivo biology, oncology, immunology, in-vitro ADME (absorption, distribution, metabolism, and excretion) studies, pharmacokinetic/pharmacodynamic studies, toxicology, and clinical bioanalysis. LTD will provide dedicated program management, streamline project coordination across WuXi, and allocate the necessary resources and R&D development efforts for Lee's Pharm programs.
"WuXi's impressive platform of lab testing services will allow our compounds to advance seamlessly through discovery, preclinical, and clinical development," Benjamin Li, executive director and CEO of Lee's Pharm, said in a press release.
Source: WuXi PharmaTech
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
